Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Historical Holders from Q1 2018 to Q3 2025

Symbol
RCUS on NYSE
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
106M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
101M
Holdings value
$1.37B
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
185
Number of buys
91
Number of sells
-86
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 25.6% -13.7% $427M 31.4M 0% GILEAD SCIENCES, INC. 03 Nov 2025
BlackRock, Inc. 9.4% $82.8M 9.98M BlackRock, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 4.1% -28% $58.9M -$20.4M 4.33M -25.7% Point72 Asset Management, L.P. 30 Sep 2025

Institutional Holders of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 101M $1.37B +$17.2M $13.60 185
2025 Q2 99.7M $811M +$23M $8.14 181
2025 Q1 97.2M $763M +$76.9M $7.85 183
2024 Q4 83.9M $1.25B -$21.2M $14.89 185
2024 Q3 53.3M $815M +$21.6M $15.29 184
2024 Q2 52M $791M -$15.7M $15.23 191
2024 Q1 52.8M $997M +$741K $18.88 169
2023 Q4 52.8M $1.01B -$1.27M $19.10 181
2023 Q3 52.8M $948M -$30.7M $17.95 184
2023 Q2 54.7M $1.11B -$11.4M $20.31 177
2023 Q1 55.5M $1.01B +$17.4M $18.24 177
2022 Q4 53.8M $1.11B +$17.7M $20.68 199
2022 Q3 52.5M $1.37B -$54.1K $26.16 171
2022 Q2 52.4M $1.33B -$16M $25.34 162
2022 Q1 50.6M $1.6B -$43.8M $31.56 146
2021 Q4 50.8M $2.06B +$107M $40.47 136
2021 Q3 48.3M $1.68B +$59.9M $34.87 127
2021 Q2 45.1M $1.24B +$11.6M $27.46 125
2021 Q1 44.7M $1.25B +$7.9M $28.08 143
2020 Q4 44.6M $1.16B +$10.4M $25.96 143
2020 Q3 44.4M $761M +$17.6M $17.14 127
2020 Q2 41.8M $1.03B +$380M $24.74 138
2020 Q1 27M $375M -$448K $13.88 92
2019 Q4 23.6M $238M -$3.03M $10.10 74
2019 Q3 25.8M $235M -$672K $9.10 73
2019 Q2 26.4M $210M +$6.02M $7.95 76
2019 Q1 25.8M $322M -$12.7M $12.49 63
2018 Q4 26.9M $290M -$4.74M $10.77 66
2018 Q3 22.4M $313M +$951K $13.94 56
2018 Q2 22.4M $274M +$31.6M $12.24 61
2018 Q1 16.3M $251M +$251M $15.44 55